Seres Therapeutics ( MCRB - Free Report ) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -20.69%. A quarter ago, it was expected that this drug developer would post a loss of $0.56 per share when it actually produced a loss of $0.61, delivering a surprise of -8.93%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Seres Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.22 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 79.84%. This compares to year-ago revenues of $5.26 million. The company has topped consensus revenue estimates just once over the last four quarters.